Dyslipoproteinemia and coronary disease

Angiology

Volumn 53, Issue 5, 2002, Pages 557-562

  Raos, Vjekoslava ^a   Strujić, Branka Jeren ^a  

^a University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERIOSCLEROSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS;

EID: 0036743242     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970205300509     Document Type: Article

References (40)

1. Kannel WB, Castelli WP, Gorton T, et al: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 74:1-2, 1971.
2. Fonarow GC, Gawlinski A: Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol 85:10A-17A, 2000.
3. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 4(suppl A):5A-10A, 1988.
4. Schectman G, Hiatt J: Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 100:197-204, 1996.
5. Sinzinger H, Pirich C, Kondor P, et al: Atherogenic risk reduction in patients with dyslipidaemia: Comparison between bezafibrate and lovastatin. Eur Heart J 16:1491-1501, 1995.
6. Ross R: The pathogenesis of atherosclerosis - an update. N Engl J Med 314:488-500, 1986.
7. Sherman CT, Litvack F, Grundfest W, et al: Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913-919, 1986.
8. Beisiegel U, St Clair RW: An emerging understanding of the interactions of plasma lipoproteins with the arterial wall that leads to the development of atherosclerosis. Curr Opin Lipidol 7:265-268, 1996.
9. Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82:3Q-12Q, 1998.
10. Assmann G, Cullen P, Schulte H: The Muster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 19(suppl A):A2-A11, 1998.
11. Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 70:733-737, 1992.
12. Boers GH: Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 78:520-522, 1997.
13. Gerhard GT, Duell PB: Homocysteine and atherosclerosis. Curr Opin Lipidol 10:417-428, 1999.
14. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775-1781, 1997.
15. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993.
16. Yasukawa H, Imaizumi T, Matsuoka H, et al: Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 95:1515-522, 1997.
17. Alexander RW: Inflammation and coronary artery disease. N Engl J Med 331:468-469, 1994.
18. Hoeg JM: Evaluating coronary heart disease risk. Tiles in the mosaic. JAMA 277:1387-1390, 1997.
19. Berliner JA, Navab M, Fogelman AM, et al: Atherosclerosis: Basic mechanisms. Oxidation, inflammation and genetics. Circulation 91:2488-2496, 1995.
20. Gimbrone MA Jr: Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75:67B-70B, 1995.
21. Anderson TJ, Gerhard MD, Meredith IT, et al: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 75:71B-74B, 1995.
22. Price JF, Fowkes FG: Risk factors and the sex differential in coronary artery disease. Epidemiology 8:584-591, 1997.
23. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987.
24. Hegele RA: Small genetic effects in complex diseases: A review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clin Biochem 30:183-188, 1997.
25. Hayek T, Oiknine J, Dankner G, et al: HDL apolipoprotein A-1 attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 33:721-725, 1995.
26. Rader DJ, Hoeg JM, Brewer HB Jr: Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 120:1012-1025, 1994.
27. Kostner KM, Huber K, Stefenelli T, et al: Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis 129:103-110, 1997.
28. Krauss RM: Dense low density lipoproteins and coronary artery disease Am J Cardiol 75:53B-57B, 1995.
29. Assmann G, Schulte H, Funke H, et al: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19(suppl M):M8-M14, 1998.
30. Gotto AM Jr: Triglyceride as a risk factor for coronary artery disease Am J Cardiol 82:22Q-25Q, 1998.
31. Jeppesen J, Hein HO, Suadicani P, et al: Triglyceride concentration and ischemic heart disease: An eight year follow-up in the Copenhagen Male Study. Circulation 97:1029-1036, 1998.
32. Miller M: Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 19(suppl H):H18-H22, 1998.
33. Scanu AM: Atherothrombogenicity of lipoprotein(a): The debate. Am J Cardiol 82:26Q-33Q, 1998.
34. Brochier ML, Arwidson P: Coronary heart disease risk factors in women. Eur Heart J 19(suppl A):A45-A52, 1998.
35. Kraft HG, Lingenhel A, Kochl S, et al: Apolipoprotein (a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16:713-719, 1996.
36. Pay S, Ozcan N, Tokgozoglu SL: Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels. Int J Cardiol 60:301-305, 1997.
37. Real JT, Chaves FJ, Martinez-Uso I, et al: Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J 22:465-471, 2001.
38. Shepherd J: A call to action. Eur Heart J 19(suppl M):M2-M7, 1998.
39. Gensini GF, Comeglio M, Colella A: Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 19(suppl A):A53-A61, 1998.
40. Chapman MJ, Guerin M, Bruckert E: Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 19(suppl A):A24-A30, 1998.